Eli Lilly and Co

FDA approves Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+ weighing at least 88 lbs. Ebglyss targets the IL-13 pathway, with 38% achieving clear or almost-clear skin at 16 weeks vs. 12% on placebo. Common AEs include eye and eyelid inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's lebrikizumab-lbkz (Ebglyss), an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years, not controlled by topical therapies. Dosed initially at 500 mg, followed by 250 mg monthly maintenance. Clinical trials showed significant skin improvement and itch relief.

FDA approves Eli Lilly's injectable eczema drug Ebglyss for adults and children 12+, targeting IL-13 protein. Available in weeks, it offers a monthly dosing option compared to competitors like Dupixent.

GLP-1 meds like Ozempic reduce risk of cirrhosis and death in diabetes patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study in JAMA Internal Medicine. Semaglutide (Ozempic/Wegovy) was particularly effective if taken early in MASLD progression. GLP-1s work by reducing body weight, blood sugar, and inflammation, potentially reversing fatty liver disease.

The FDA approved lebrikizumab (Ebglyss) for moderate to severe atopic dermatitis in patients aged 12+ weighing at least 88 lbs. This IL-13 inhibitor offers a new first-line biologic treatment, especially for those not well-controlled by topical therapies. It can be used with or without topical corticosteroids, with a recommended initial dose of 500 mg followed by 250 mg every 2 weeks until week 16, then monthly maintenance. Lebrikizumab is expected to be available in the US soon and has already been approved in Europe and Japan.

Drugmakers like Bristol Myers Squibb, AstraZeneca, and Eli Lilly invest billions in radiopharmaceuticals, which deliver radiation directly to tumors. These drugs, in development for various cancers, attach radioactive material to targeting molecules, sparing healthy cells. Novartis' successes with Lutathera and Pluvicto have spurred interest, but manufacturing and logistics remain complex. The market potential ranges from $5 billion to tens of billions, depending on efficacy across cancer types.

Johnson & Johnson plans phase 3 trials for Rybrevant in colorectal cancer after phase 1b/2 OrigAMI-1 study showed 49% ORR in RAS/BRAF wild-type mCRC patients, with 7.4 months median duration of response and 88% disease control rate. Rybrevant also achieved 53% ORR in liver-metastasized cases, with 21% eligible for curative surgery.

Pharmacist Mark Mikhael credits weight loss drugs for his 50-pound weight loss and improved health. He and other industry officials estimate that large compounding pharmacies are provisioning millions of American patients with semaglutide and tirzepatide, despite opposition from drug-making giants like Novo Nordisk and Eli Lilly. The FDA allows compounding pharmacies to produce and sell copycats when drugs are in short supply, but the raw materials used may differ, potentially causing harmful immune reactions. The compounded forms are significantly cheaper than the branded drugs, leading to concerns about quality and safety.

Eli Lilly's targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) approved by FDA for moderate-to-severe atopic dermatitis in adults and adolescents aged 12+ with at least 40kg body weight, not well controlled by topical therapies. Ebglyss, effective with or without topical corticosteroids, showed 38% of patients achieving clear or almost-clear skin at week 16 in ADvocate trials, compared to 12% with placebo.